Drug intelligence / Profile preview

afzelin

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intracerebral (research Use)
01

Overview

Afzelin is a naturally occurring flavonoid glycoside, chemically known as kaempferol-3-O-rhamnoside, and is found in multiple plant species, especially in Thesium chinense and Cornus macrophylla[1][4][8][14]. Afzelin has **anti-inflammatory**, **antioxidant**, **anti-apoptotic**, **antibacterial**, **DNA-protective**, and **cardioprotective** properties[1][9][15][16]. Its mechanisms include modulating cellular pathways associated with inflammation (notably MAPK and NF-κB), oxidative stress, and apoptosis[3][16]. It acts as an **aldose reductase inhibitor** (AR), modulates **CREB-BDNF signaling**, and upregulates proteins such as AMPKα and SIRT1[1][3]. Preclinical research supports its neuroprotective activity (notably ameliorating synaptic plasticity and cognitive deficits in animal models), its potential activity against neurodegenerative diseases (such as Alzheimer's and Parkinson's), asthma (via GATA3 inhibition), doxorubicin-induced cardiotoxicity, and anti-cancer effects through apoptosis and inflammation inhibition[1][3][5][7].

Other names
kaempferol-3-O-rhamnosidekaempferol3-O-rhamnosidekaempferol 3-O-rhamnosidekaempferinkaempferol 3-O-α-L-rhamnopyranosidekaempferol 3-rhamnosidekaempferol3-rhamnosidekaempferol-3-rhamnosideafzelosidekaempferol 3-O-glucorhamnosidekaempferol3-O-glucorhamnosidekaempferol-3-O-glucorhamnoside
02

Targets

AcetylcholinesteraseTYR (Tyrosinase)Sucrase-IsomaltaseAR (Adrenergic receptors)DNA gyrase

Beyond the preview

Go deeper on afzelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on afzelin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call